Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Authors
Middleton, GSilcocks, P
Cox, T
Valle, Juan W
Wadsley, J
Propper, D
Coxon, F
Ross, P
Madhusudan, S
Roques, T
Cunningham, D
Falk, S
Wadd, N
Harrison, M
Corrie, Pippa
Iveson, Tim
Robinson, A
McAdam, K
Eatock, M
Evans, J
Archer, C
Hickish, T
Garcia-Alonso, A
Nicolson, M
Steward, W
Anthoney, A
Greenhalf, W
Shaw, V
Costello, E
Naisbitt, D
Rawcliffe, C
Nanson, G
Neoptolemos, J
Affiliation
University of Birmingham, Edgbaston, Birmingham, UK.Issue Date
2014-07
Metadata
Show full item recordAbstract
We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.Citation
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. 2014, 15 (8):829-40 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(14)70236-0PubMed ID
24954781Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(14)70236-0
Scopus Count
Collections
Related articles
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
- Authors: Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T
- Issue date: 2013 Apr
- Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
- Authors: Middleton G, Greenhalf W, Costello E, Shaw V, Cox T, Ghaneh P, Palmer DH, Neoptolemos JP
- Issue date: 2016 Mar 1
- Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.
- Authors: Staff C, Mozaffari F, Frödin JE, Mellstedt H, Liljefors M
- Issue date: 2014 Sep
- Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
- Authors: Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V, German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators
- Issue date: 2021 Feb
- Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
- Authors: Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C
- Issue date: 2017 May